Inhibiting SCD Expression by IGF1R during Lorlatinib Therapy Sensitizes Melanoma to Ferroptosis

The authors used a drug synergy screen that combined a ferroptosis inducer, RSL3, with 240 anti-tumor drugs from the FDA-approved drug library and identified lorlatinib to synergize with RSL3 in melanoma cells.